Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Novosibirsk State University | OTHER |
Not provided
Not provided
Not provided
Not provided
This retrospective cohort study evaluates the association between H. pylori persistence and insulin resistance severity (HOMA-IR) in 100 patients with metabolic syndrome at Novosibirsk's Center for New Medical Technologies (CNMT). Patients are divided into infected (n=50) and non-infected (n=50) groups, assessing metabolic parameters, gastro panel, and CRP. Primary endpoint: HOMA-IR differences; secondary: correlations with gastric inflammation and metabolic markers.
This retrospective cohort study evaluates the association between H. pylori persistence and insulin resistance severity.
Relevance Metabolic syndrome (MS) is a major public health issue due to its high prevalence and role in type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular diseases. Insulin resistance (IR) is a key pathogenetic factor in MS. Recent meta-analyses confirm a significant association between H. pylori infection and increased MS and IR risk, highlighting the need to explore H. pylori's role in metabolic disorders.
Chronic H. pylori-induced inflammation may promote low-grade systemic inflammation, worsening carbohydrate metabolism, supported by meta-analytic and cohort studies. Elevated pro-inflammatory cytokines and C-reactive protein (CRP) act as mediators of insulin sensitivity impairment. H. pylori eradication effects on metabolic parameters vary, necessitating clarification of infection persistence's impact on IR in MS patients.
Hypothesis, Aim, and Objectives Hypothesis: Chronic inflammation from H. pylori exacerbates systemic inflammation and deteriorates metabolic parameters, including IR indices.
Primary Aim: Establish the presence and nature of correlation between H. pylori persistence and IR severity (via HOMA-IR) in verified MS patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| group with persistence of H. pylori | group with metabolic syndrome and persistence of H. pylori | ||
| group without persistence of H. pylori | group without metabolic syndrome and persistence of H. pylori |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Difference in HOMA-IR index between H. pylori-positive and -negative patients. | Any difference between groups according to the HOMA-IR index | No more than 2 days after inclusion in the study |
| Measure | Description | Time Frame |
|---|---|---|
| CRP level differences | any differences between groups in C-reactive protein levels (mg/L) | No more than 2 days from the date of inclusion in the study |
| difference in body mass index levels | any differences between groups in terms of body mass index (kg/m²) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with metabolic syndrome
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Evgeniya V Shrainer, PhD | Contact | 983 300 22 05 | +7 | shrayner_ev@cnmt.ru |
| Elizaveta K Nemkova, MD | Contact | 9512732447 | +7 | nemkova_ek@cnmt.ru |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center of New Medical Technologies | Recruiting | Novosibirsk | Novosibirsk Oblast | 630090 | Russia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D024821 | Metabolic Syndrome |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| No more than 2 days from the date of inclusion in the study |
| difference in waist circumference | any differences between groups in waist circumference (cm) | No more than 2 days from the date of inclusion in the study |
| difference in fasting glucose levels | any differences between groups in fasting glucose levels (mmol/L) | No more than 2 days from the date of inclusion in the study |
| difference in triglyceride levels | any differences between groups in triglyceride levels (mmol/L) | No more than 2 days from the date of inclusion in the study |
| difference in total cholesterol levels | any differences between groups in total cholesterol levels (mmol/L) | No more than 2 days from the date of inclusion in the study |
| difference in low-density lipoprotein levels | any differences between groups in low-density lipoprotein levels (mmol/L) | No more than 2 days from the date of inclusion in the study |
| difference in high-density lipoprotein levels | any differences between groups in high-density lipoprotein levels (mmol/L) | No more than 2 days from the date of inclusion in the study |
| difference in the atherogenic index | any differences between groups in atherogenic index | No more than 2 days from the date of inclusion in the study |